Featured conditions Brain tumor, breast cancer, colon cancer, congenital heart disease, heart arrhythmia. See more conditions.
Featured conditions
(for at least one location)
Jacksonville, FL
Describes the nature of a clinical study. Types include:
The purpose of this study is to investigate ghrelin, a peptide that mechanistically carries the promise of therapeutics benefit for diverse aspects of morbidity associated with lung transplantation.
Study statuses change often. Please contact us for help.
Open for enrollment
Scottsdale/Phoenix, AZ
Hypothesis: we hypothesize that the abundance and functions of Breg subsets in kidney transplant patients could be associated with transplant tolerance and rejection, including DSA-mediated kidney transplant rejection. In addition, oral corticosteroid treatment significantly alters the frequency and function of Breg subsets, which could lead altered clinical outcomes. Aims, purpose, or objectives: 1. Investigate the frequency Bregs and their ability to express IL-10 along with other immune cells in the context of tolerance/rejection in kidney transplant patients. we hypothesize that the abundance and functions of Breg subsets in kidney transplant patients could be associated with transplant tolerance and rejection, including DSA-mediated kidney transplant rejection. 2.Investigate the frequency and functions of Bregs along with other immune cells in the setting of long term corticosteroid use. We hypothesize that oral corticosteroid treatment significantly alters the frequency and function of Breg subsets, which could lead altered clinical outcomes.
The purpose of this study is to determine the safety of the SARS-CoV-2 vaccination in patients listed for solid organ transplantation, including heart, lung, liver, kidney, and pancreas.
Rochester, MN
The purpose of this study is to evaluate the immune and hematopoietic compartments in patients with monoclonal B cell lymphocytosis (MBL) and chronic lymphocytic leukemia (CLL) in comparison to age-matched healthy control (HC) donors.
Contact us for the latest status